Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -2.75% | |
| 50 DMA Support | Bullish | -2.75% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.75% | |
| Pocket Pivot | Bullish Swing Setup | -2.75% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 22 hours ago |
| 20 DMA Resistance | about 22 hours ago |
| 2x Volume Pace | about 22 hours ago |
| 1.5x Volume Pace | about 22 hours ago |
| 3x Volume Pace | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Dementia Stroke Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Dementia Stroke Ischemia Kallikrein Pancreatitis Acute Pancreatitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.95 |
| 52 Week Low | 2.12 |
| Average Volume | 52,006 |
| 200-Day Moving Average | 3.28 |
| 50-Day Moving Average | 4.24 |
| 20-Day Moving Average | 4.37 |
| 10-Day Moving Average | 4.33 |
| Average True Range | 0.20 |
| RSI (14) | 47.37 |
| ADX | 18.85 |
| +DI | 18.56 |
| -DI | 17.23 |
| Chandelier Exit (Long, 3 ATRs) | 4.16 |
| Chandelier Exit (Short, 3 ATRs) | 4.66 |
| Upper Bollinger Bands | 4.56 |
| Lower Bollinger Band | 4.19 |
| Percent B (%b) | 0.17 |
| BandWidth | 8.43 |
| MACD Line | 0.03 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.0215 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.78 | ||||
| Resistance 3 (R3) | 4.77 | 4.58 | 4.69 | ||
| Resistance 2 (R2) | 4.58 | 4.45 | 4.59 | 4.66 | |
| Resistance 1 (R1) | 4.42 | 4.37 | 4.33 | 4.43 | 4.63 |
| Pivot Point | 4.23 | 4.23 | 4.19 | 4.24 | 4.23 |
| Support 1 (S1) | 4.07 | 4.10 | 3.98 | 4.08 | 3.87 |
| Support 2 (S2) | 3.88 | 4.02 | 3.89 | 3.84 | |
| Support 3 (S3) | 3.72 | 3.88 | 3.81 | ||
| Support 4 (S4) | 3.73 |
